

## **September 12, 2018**

Medical Information Technology, Inc. Attention: Mr. Philip Polimeno Meditech Circle Westwood, MA 02090

Re: BK180219

Trade/Device Name: MEDITECH Expanse Blood Bank

Regulation Number: 21 CFR 864.9165

Regulation Name: Blood Establishment Computer Software and Accessories

Regulatory Class: Class II Product Code: MMH

Dated: September 11, 2018 Received: September 11, 2018

## Dear Mr. Polimeno:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801; medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

<u>http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm</u> for more information.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<a href="https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/">https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/</a>) and CDRH Learn (<a href="http://www.fda.gov/Training/CDRHLearn">http://www.fda.gov/Training/CDRHLearn</a>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<a href="http://www.fda.gov/DICE">http://www.fda.gov/DICE</a>) for more information or contact DICE by email (<a href="DICE@fda.hhs.gov">DICE@fda.hhs.gov</a>) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Orieji Illoh, MD Director Division of Blood Components and Devices Office of Blood Research and Review Center for Biologics Evaluation and Research

Enclosure Indications for Use

T 10	_ •	•	<b>T</b> T
Indi	cation	is tor	LISE

Device Name: MEDITECH Expanse Blood Bank

Indications for Use:

The MEDITECH Blood Bank Software provides a variety of functionality for healthcare personnel. The software helps personnel, in both multiple and single facility organizations, manage their departments more efficiently by integrating donor, unit, and patient information.

The MEDITECH Blood Bank Software assists with:

Tracking of donor products from receipt to final disposition Specimen crossmatching Specimen electronic crossmatching Determining the suitability of released products upon issuing Recording of transfusion information Tracking product disposition

The MEDITECH Blood Bank Software interfaces to the following Blood Bank Analyzer for the purposes of specimen resulting and transmitting the results to the MEDITECH Blood Bank Software:

Galileo Echo

The software also allows online inquiries and permanent storage of:

Donor history Crossmatch results Antigens/Antibodies Transfusion data Unit history Patient's comprehensive blood bank history

Prescription Use X	AND/OR	Over-The-Counter Use	
(Part 21 CFR 801 Subpart D)	•	(21 CFR 801 Subpart C)	

(PLEASE DO NOT WRITE BELOW LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CBER, Office of Device Evaluation (ODE)

Division Sign-Off, Office of Blood Research and Review